Background {#Sec1}
==========

Ventilator-associated pneumonia (VAP) is the most common nosocomial infection in the intensive care unit (ICU), resulting in a high burden of illness. In a 2005 systematic review, the pooled cumulative incidence of VAP was 23 % (95 % confidence interval (CI) 18.8 %--26.9 %) in randomized controlled trials (RCTs) and 10 % (95%CI 7.0--12.5 %) in observational studies \[[@CR1]\]. In addition, VAP is associated with a two-fold attributable risk of dying in the ICU (odds ratio (OR) 2.02, 95 % CI 1.16--3.56), and the cost attributed to VAP ranges from US \$10,000--\$13,000 per patient \[[@CR1]\]. Thus, VAP prevention is an important patient safety goal for critically ill patients \[[@CR2], [@CR3]\].

Probiotics, which are live microorganisms thought to have health benefits when ingested, \[[@CR4]\] have emerged as a potential strategy to prevent VAP, potentially through enhancing gut barrier function and reducing pathogenic bacterial load \[[@CR5], [@CR6]\]. An early systematic review and meta-analysis of RCTs evaluating the efficacy of probiotics on VAP prevention in the ICU conducted in 2010 that included five RCTs showed that probiotics compared with control (placebo or other) reduced the incidence of VAP in mechanically ventilated patients (60/316 (19 %) versus 102/373 (27 %), OR 0.55, 95 % CI 0.31--0.98, *I*^2^ 39 %) \[[@CR7]\]. The most rigorous RCT to date compared a combination of oropharyngeal plus gastric *Lactobacillus rhamnosus* GG to corresponding placebos in 146 patients expected to remain intubated for at least 72 hours (a group at relatively high risk of VAP) \[[@CR8]\]. Those patients treated with *L. rhamnosus* GG had lower rates of VAP (17/73 (23 %) versus 33/73 (45 %), relative risk (RR) 0.46, 95 % CI 0.26--0.82). This trial suggests that *L. rhamnosus* GG, specifically, is a promising probiotic to prevent VAP in a selected high-risk ICU population.

Our recent meta-analysis of RCTs in the ICU suggests that probiotics administered to critically ill mechanically ventilated patients are associated with a 25 % lower VAP rate (95 % CI 3--41 %) and 18 % lower infection rates overall (95 % CI 1--31 %) \[[@CR9]\]. However, the finding that probiotics may prevent VAP arise from seven small (*n* = 50--300), mostly low quality single-center RCTs yielding imprecise estimates and results with uncertain internal and external validity.

Given the effectiveness of probiotics in the community and hospital setting \[[@CR10]--[@CR13]\], yet uncertain benefits in the ICU, a large rigorous RCT is needed. Before launching a complex costly RCT testing whether probiotics confer benefit, harm, or have no impact on infectious and non-infectious outcomes, a pilot trial is crucial. To this end, we sought to determine whether it is feasible to perform a large RCT in mechanically ventilated critically ill patients to investigate whether orally ingested *L. rhamnosus* GG prevents VAP based on successful and timely pilot trial recruitment, high adherence to protocol, minimal contamination, and an acceptable VAP rate in the Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization (PROSPECT) Pilot Trial. Ultimately, if the pilot trial is successful, the main trial will aim to determine, among mechanically ventilated critically ill patients, the effect of orally ingested *L. rhamnosus* GG compared to placebo on VAP and other ICU-acquired infections, diarrhea (including total, antibiotic associated and C. difficile), the duration of mechanical ventilation, ICU and hospital stay, and ICU and hospital mortality (PROSPECT Trial NCT01782755).

Methods/design {#Sec2}
==============

Study design {#Sec3}
------------

We are conducting a parallel group blinded pilot RCT in 14 ICUs in Canada and the United States. Patients are randomized to placebo or probiotic in a fixed allocation ratio of 1:1 using a computer based random number generator produced on the RANDOMIZE.NET website. Randomization is concealed and stratified by ICU and by medical, surgical, or trauma status, in variable unspecified block sizes. Research Coordinators screen all ventilated patients during weekdays. A de-identified log of screened patients is kept, recording each inclusion/exclusion criteria. Reasons for being eligible non-randomized are recorded. Once the Research Coordinator determines that a patient is truly eligible, s/he obtains written informed a priori consent either from the patient or substitute decision maker then notifies the local study pharmacist who performs the randomization.

After randomization, an identical placebo ensures blinding of all possible parties (patient, family, bedside clinicians, laboratory and research personnel, the biostatistician and data analyst).

Eligibility {#Sec4}
-----------

Inclusion criteria:Adults ≥18 years old in the ICU;Mechanically ventilated with anticipated ventilation of ≥72 hours at enrolment.

Exclusion criteria:Mechanical ventilation exceeding 72 hours at time of screening;Increased risk of iatrogenic probiotic infection including specific immunocompromised populations (HIV \<200 CD4 cells/μL, chronic immunosuppressive medications, prior organ or hematological transplant, neutropenia (absolute neutrophil count \<500);Increased risk for endovascular infection (history of rheumatic heart disease, congenital heart defect, mechanical valves, endocarditis, endovascular grafts, permanent endovascular devices such as permanent (not short-term) hemodialysis catheters, pacemakers or defibrillators);Mucosal gastrointestinal tract defects (gastroesophageal or intestinal injury, including active bleeding), surgery of the esophagus, stomach, small or large bowel, liver, gallbladder, hepatobiliary tree, spleen, or pancreas within 72 hours, suspected or documented ischemic gut and severe acute pancreatitis, \[[@CR14]\]);Strict contraindication or inability to receive enteral medications;Pregnancy;Intent to withdraw advanced life support;Enrolment in this or an ongoing related trial.

### Trial interventions {#Sec5}

Patients allocated to the intervention receive 1 × 10^10^ colony forming units (CFU) of *L. rhamnosus* GG (Culturelle, Locin Industries Ltd) in one capsule suspended in tap water, administered via nasogastric or nasoduodenal tube twice daily in the ICU. *L. rhamnosus* GG, a variant to *L. casei rhamnosus* is the most widely studied in adults and children \[[@CR15]\]. *L. rhamnosus* GG is approved in Canada for managing and preventing antibiotic-associated diarrhea (Health Canada Natural Product \#80011341). The most rigorous RCT to date investigating probiotics for the prevention of VAP used *L. rhamnosus* GG as the intervention, and the results of this pilot trial suggest that *L. rhamnosus* GG is a promising option for preventing VAP \[[@CR8]\]. Furthermore, recent in vivo studies showed that a dose of *L. rhamnosus* GG of ≥1 × 10^9^ was optimal to reduce bacteremia and mortality from peritonitis and pneumonia \[[@CR16]\]. This dose could reduce intestinal epithelial apoptosis and restore colonic epithelial cell proliferation and attenuate the local and systemic inflammatory response, potentially by downregulation of TLR-2/TLR-4 signalling pathway in the colon. \[[@CR16]\]. The dose we are using is higher than the dose showing prevention of VAP in the Morrow RCT (total of four billion *L. rhamnosus* GG) \[[@CR8]\] and the same dose as another RCT investigating *L. rhamnosus* GG in ICU patients as a potential therapy for diarrhea (total of 20 billion *L. rhamnosus* GG) \[[@CR17]\]. Neither trial observed adverse events related to *L. rhamnosus* GG \[[@CR8], [@CR17]\].

Patients allocated to placebo will receive microcrystalline cellulose, which will also be suspended in tap water, identical in appearance and consistency to the probiotic, and similarly administered. The placebo is prepared by the manufacturer of *L. rhamnosus* GG, Culturelle, as used in a recent trial \[[@CR8]\]. Patients will receive the study product until (1) death or discharge from ICU, or (2) isolation of *Lactobacillus* spp. cultured from a sterile site or reported as the sole or predominant organism in a culture from a non-sterile site or, (3) 60 days post randomization.

To ensure consistency and document that the probiotic dose matches the label, one capsule from every 10 sheets is being cultured and quantified in the Surette Laboratory at McMaster University.

### Outcomes {#Sec6}

The four feasibility outcomes will be:Recruitment of trial patients. Successful recruitment is defined as ≥2 patients per month (total from any study site) on average. This outcome is important because unforeseen enrolment challenges are crucial to identify in a pilot RCT. Unrealistic projected recruitment rates for large studies lead to trial fatigue, threaten non-completion, and generate major cost overruns. Screening logs are being reviewed monthly and eligible non-randomized patients are examined. Barriers to enrolment are discussed and strategies to improve recruitment are being devised. We will calculate the mean (standard deviation) number recruited across all recruiting centers per month.Adherence to protocol. Successful adherence is defined as ≥90 % of the prescribed intervention being administered. There are many reasons why ICU patients do not receive drugs administered through the feeding tube. Research Coordinators determine doses actually received and reasons for non-administration using taxonomy. If patients cannot tolerate continuous enteral feeds, they will still usually be able to receive the study product in a small volume of fluid, akin to administering pills or capsule medications. Understandable protocol deviations (e.g., patient died) are being distinguished from protocol violations (e.g., missed doses). We will calculate an overall proportion of doses received divided by total doses prescribed (with 95 % confidence interval).Contamination. Success is defined if \<5 % of patients have any non-study open-label probiotic, in either group, during the ICU stay. The proportion of patients contaminated with any open-label probiotic is being recorded by Research Coordinators daily. We will calculate the total number of patients who ever had open-label probiotics as a proportion (with 95 % confidence intervals) of all randomized patients.VAP. Success is defined if \>10 % patients develop VAP overall. This outcome is important because the widely cited data by quality of care and patient safety initiatives are biased by underreporting, generating such low VAP rates that selecting this as a primary trial outcome would make the sample size prohibitively large. A valid contemporaneous rate of VAP will be essential to calculate the sample size for a future large trial. We will calculate the proportion of patients with VAP (with 95 % confidence intervals). Research Coordinators are submitting relevant clinical, radiologic, and microbiologic data to the Methods Center from patients with clinically suspected VAP when there is a new, progressive or persistent radiographic infiltrate with no other obvious cause and the presence of any two of the following symptoms or signs: (1) fever (temperature \>38 °C) or hypothermia (temperature \<36 °C), (2) relative neutropenia (\<3.0 × 10^6^/L) or leukocytosis (\>10 × 10^6^/L), and (3) purulent sputum \[[@CR18]\]. VAP will also be classified several other ways such as clinically suspected and treated VAP, according to the Clinical Pulmonary Infection Score \[[@CR19]\] and as adjudicated by independent blinded physicians using previous methods \[[@CR20]--[@CR22]\].

No significance testing between groups is needed to analyze these feasibility objectives. Analyses will be performed at the end of the trial on the cohort of enrolled patients; data will not be divided by allocation group to retain the blinding. No interim analyses or subgroup analyses are planned due to the short duration and sample size of this pilot trial.

### Clinical outcomes {#Sec7}

These outcomes are being recorded in the PROSPECT Pilot Trial as well as the main trial.VAP as described above;Other infections defined using an adaptation of the International Sepsis Forum Consensus Conference on Definitions of Infections in the ICU \[[@CR22]\];C. difficile-associated diarrhea defined as three or more episodes of unformed stools in ≤24 hours, and C. difficile toxin positive stool or colonoscopic or histopathologic findings demonstrating pseudomembranous colitis \[[@CR23]\];Antibiotic-associated diarrhea defined as more than two liquid stools a day for three or more days in quantities in excess of normal for each patient \[[@CR24]\];Diarrhea according to the Bristol Stool Chart (1--7);Duration of mechanical ventilation, length of ICU stay, and length of hospital stay;ICU mortality and in-hospital mortality.

### Serious adverse events {#Sec8}

The rationale for our approach to serious adverse events (SAEs) accord with our guidelines for academic critical care trials of common interventions \[[@CR25]\]. Thus, defined a priori, plausible SAEs have been incorporated as trial outcomes. Any other events that ICU physicians or Site Investigators label as SAEs will be described fully. Any cultures by the ICU team found to be positive for *Lactobacillus* spp. will have the sample sequenced to determine whether it is consistent with the administered *L. rhamnosus* GG strain. *Lactobacillus* spp. identified in a sterile site or cultured as the sole or predominant organism in a non-sterile site will prompt study product discontinuation.

Follow-up {#Sec9}
---------

Patients are being reviewed daily by the Research Coordinator in ICU, where most information is collected. This involves baseline data (e.g., demographics, illness severity, advanced life support), daily data (e.g., study intervention administration and reasons why not administered, nutritional route, relevant medications including antibiotics, agents that may increase gut motility (e.g., prokinetics, laxatives) or decrease gut motility (e.g., opiate infusions), VAP prevention co-interventions, culture results, clinical diagnoses, diarrhea episodes, length of stay, mortality), and Methods Center data (e.g., infection adjudication forms). Any reasons for protocol non-compliance are recorded daily, along with any contamination by non-study probiotic. Co-interventions will likely be comparable between groups, given the blinded design, but they are recorded daily, including other VAP prevention strategies and antibiotics (type, dose, frequency and duration). We do not anticipate any patients lost to follow-up given the hospital time horizon for vital status ascertainment and the ICU stay for key data collection.

Ethics {#Sec10}
------

The protocol has been approved by each hospital's Research Ethics Board using an a priori consent model. PROSPECT is being conducted in accordance with Good Clinical Practice following the Tri-council Guidelines.

This is an investigator-initiated trial funded from four peer review sources to minimize possible financial conflict of interests. Probiotic and placebo were donated by iHealth, the distributers of Culturelle's *L. rhamnosus GG* product.

This Pilot Trial does not have a Data Safety and Monitoring Committee (DSMC) due to its size and duration. The larger trial's independent DSMC will create a charter \[[@CR26]\] outlining roles, responsibilities, and reporting relationships. For the future large trial, the Trial Biostatistician will provide the DSMC with blinded reports of protocol adherence (e.g., randomization, crossovers, etc.), management indicators (e.g., consent rate, data completion), and clinical outcomes (in interim and final analyses).

Sample size and recruitment {#Sec11}
---------------------------

Our approach to sample size for a pilot trial focused on feasibility was based on interpreting the lower bound of confidence intervals around estimates \[[@CR27]\]---in this case, around the feasibility objective of adherence to protocol, whereby successful adherence is defined as ≥90 % of the prescribed intervention being administered. Using patient as the unit of analysis, rather than doses prescribed, the PROSPECT Pilot Trial sample size calculation claims feasibility if at least 80 % of the patients can achieve successful protocol adherence. Recruiting only 150 patients gives an estimate of the proportion of patients with successful adherence with a margin of error between 0.05 and 0.06 in a 95 % CI with a lower bound of 0.84 \[Appendix\]. However, we increased the sample size into the vanguard Pilot Trial phase to enrol 250 patients in 14 ICUs, for the following reasons: (1) to be sure that at a large number of centers, there is sufficient Research Coordinator exposure to the protocol; (2) to identify any feasibility challenges with data collection methods for the various complex nosocomial infections that could occur at any of the centers with different referral patterns and case mix; and (3) to be sure that we can evaluate our key feasibility objectives in both Canada and the United States \[[@CR28]\].

For the future main PROSPECT Trial, the target sample size will be 2650 patients. Based on an estimated 15 % VAP rate, 1325 patients in each group (*n* = 2650) will be enrolled to detect a 25 % relative risk reduction with 80 % power (alpha 0.05, beta 0.80), using a two-tailed chi-square test.

Management {#Sec12}
----------

To ensure protocol adherence and data quality, training sessions were held for all research personnel using procedures manuals, standard operating procedures, slide decks, and a study website. The PROSPECT Steering Committee is responsible for the conduct of this PROSPECT Pilot Trial, for upholding or modifying study procedures as needed, addressing challenges with protocol implementation, refining the protocol as needed, and reviewing the data. Steering Committee meetings are held in-person or by conference call quarterly. The Clinical Advances through Research and Information Translation (CLARITY) Research Group at McMaster University is responsible for overall management. We have the requisite breadth and depth of knowledge in study design, implementation, and biostatistics. Our faculty and staff have a wealth of experience in implementation of pilot studies and large international, national, and provincial randomized trials and observational studies. CLARITY has extensive experience and published on calibration, adjudication and efficiencies therein for VAP \[[@CR21]\], bleeding \[[@CR28]\], lung cancer \[[@CR29]\], and thrombosis \[[@CR30]--[@CR32]\]. The PROSPECT Pilot Trial is conducted under the auspices of the Canadian Critical Care Trials Group \[[@CR33], [@CR34]\].

Discussion {#Sec13}
==========

Pilot trials have served the Canadian Critical Care Trials Group well \[[@CR27], [@CR35]\], preparing for larger trials. If all four of our PROSPECT Pilot Trial feasibility objectives are attained, we will be well positioned to pursue the main trial. If any of our feasibility objectives are not met, we will rework the protocol in collaboration with the CCCTG and only move forward if the barriers can be properly addressed. The PROSPECT Pilot Trial takes a financially responsible approach to establish research efficiencies and economies of scale before costly grant applications are prepared. If the pilot RCT does not identify a need for any substantive protocol changes, this will be an internal pilot \[[@CR35]\]. Accordingly, we will not analyze or report clinical outcomes from the pilot trial; we will include these patient data in the analyses of the main PROSPECT Trial.

Strengths of this proposed trial include rigorous design, inclusion of an inexpensive widely available intervention and multicenter, international enrolment to maximize generalizability. Understanding and reducing potential barriers to enrolment is a critical aim of the PROSPECT Pilot Trial. Rates of consent are influenced by the institutional setting, research infrastructure, and experience of the investigators and research staff \[[@CR36]\] as well as physician-specific concerns \[[@CR37]\]. It is therefore essential to carefully record and monitor enrolment practices and make improvements where possible. We have successfully conducted other international trials \[[@CR38]--[@CR42]\] and are interested to evaluate co-enrolment across participating centers and countries \[[@CR43]\]. When thoughtfully approached, co-enrolment has not been found to impact on trial results \[[@CR43], [@CR44]\], and thus, ways to maximize safe co-enrolment opportunities will be explored in this trial.

It is important to understand whether probiotics are helpful, harmful, or have no effect in vulnerable critically ill patients. The PROSPECT Pilot Trial is foundational to this goal. If the future larger PROSPECT Trial shows that probiotics are effective at preventing VAP, C. difficile, or any infections in the ICU, use may increase. Conversely, if the findings suggest harm or no effect, the reverse is likely. The forthcoming Canadian VAP Prevention Practice Guidelines which currently "suggest" that probiotics are considered in practice (J Muscedere, personal communication, 2015), may, in future updates, either remain the same, change to "recommend" probiotics, or recommend against them, depending on our findings.

Trial status {#Sec14}
------------

Enrolment is underway in the pilot trial.

Appendix {#Sec15}
========

PROSPECT Pilot Trial sample size {#Sec16}
--------------------------------

The sample size for the PROSPECT Pilot Trial was calculated considering a feasibility objective of adherence to protocol, whereby successful adherence is defined as ≥90 % of prescribed intervention being administered. For the sample size of patients, patients are necessarily the unit of analysis rather than doses prescribed. We will consider the trial *feasible if at least 80 % of the patients can achieve successful protocol adherence*. We based the calculations on the formula for the sample size for a single proportion, based on a confidence interval approach$$\documentclass[12pt]{minimal}
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where *n* is the required sample size, *p* is the prior estimate of the proportion of patients with successful protocol adherence, z~α/2~ = 1.96 is the *z*-score, a tabulated value of the standard normal distribution corresponding to a probability value of 0.05, corresponding to the 95 % confidence interval (CI), and ME is the margin of error. We created a table providing different values of the sample size (*n*) based on two prior estimates (PE) of *p*, 0.90 and 0.85, different margins of error (ME), calculated such that the lower confidence bound (LCB) of the estimated confidence interval estimate will be at least 0.80. In the PROSPECT Pilot Trial we plan to recruit *n* = 150 patients, and based on a prior estimate of PE = 0.90, this will give us an estimate of the proportion of patients with successful adherence with margin of error between 0.05 and 0.06 and a 95 % CI with a lower bound of 0.84.
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